Cargando…

Bispecific T cell engagers targeting CD20/CD3 in B-cell lymphoma: latest updates from 2023 EHA annual meeting

Detalles Bibliográficos
Autores principales:	Jin, Shenhe, Liu, Yi, Zhang, Ye, Zhou, Fengping, You, Liangshun, Zhang, Jin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10697048/ http://dx.doi.org/10.1177/20406223231215701

Ejemplares similares

CD20 × CD3 bispecific antibodies for lymphoma therapy: latest updates from ASCO 2023 annual meeting
por: Liu, Xinyuan, et al.
Publicado: (2023)

Bispecific antibody treatment of multiple myeloma: latest updates from the 2022 ASH annual meeting
por: Yin, Xuejiao, et al.
Publicado: (2023)

Bispecific antibodies and dual-targeting CAR-T cells for multiple myeloma: latest updates from the 2023 ASCO annual meeting
por: Hou, Jiangxue, et al.
Publicado: (2023)

Correction to: Bispecific antibodies and dual-targeting CAR-T cells for multiple myeloma: latest updates from the 2023 ASCO annual meeting
por: Hou, Jiangxue, et al.
Publicado: (2023)

Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting
por: Zhao, Juanjuan, et al.
Publicado: (2023)

Development of a Bispecific Nanobody Targeting CD20 on B-Cell Lymphoma Cells and CD3 on T Cells
por: Liu, Yanlong, et al.
Publicado: (2022)

Antitumor activity of T cells secreting αCD133-αCD3 bispecific T-cell engager against cholangiocarcinoma
por: Sangsuwannukul, Thanich, et al.
Publicado: (2022)

EHA Research Roadmap on Hemoglobinopathies and Thalassemia: An Update
por: Iolascon, Achille, et al.
Publicado: (2019)

BCMA-targeted CAR-T cell therapies in relapsed and/or refractory multiple myeloma: latest updates from 2023 ASCO Annual Meeting
por: Wu, James F., et al.
Publicado: (2023)

Simultaneous Multiple Interaction T-cell Engaging (SMITE) Bispecific Antibodies Overcome Bispecific T-cell Engager (BiTE) Resistance Via CD28 Co-Stimulation
por: Correnti, Colin E., et al.
Publicado: (2018)

Bispecific antibodies as monotherapy or in combinations for non-hodgkin B-cell lymphoma: latest updates from the American society of hematology 2022 annual meeting
por: Lin, Zhijuan, et al.
Publicado: (2023)

The making of multivalent gamma delta TCR anti-CD3 bispecific T cell engagers
por: van Diest, Eline, et al.
Publicado: (2023)

Anti-CD22/CD20 Bispecific Antibody with Enhanced Trogocytosis for Treatment of Lupus
por: Rossi, Edmund A., et al.
Publicado: (2014)

Binding domain on CD22 molecules contributing to the biological activity of T cell-engaging bispecific antibodies
por: Chen, Jie, et al.
Publicado: (2023)

A Preclinical Population Pharmacokinetic Model for Anti‐CD20/CD3 T‐Cell‐Dependent Bispecific Antibodies
por: Ferl, Gregory Z., et al.
Publicado: (2018)

COVID-19 infection outcomes in patients receiving CD20 targeting T-cell engaging bispecific antibodies for B-cell non-Hodgkin lymphoma
por: Nachar, Victoria R., et al.
Publicado: (2023)

Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia
por: Wu, Jingjing, et al.
Publicado: (2015)

Targeting the CD47-SIRPα signaling axis: current studies on B-cell lymphoma immunotherapy
por: Zhang, Jin, et al.
Publicado: (2018)

Flavor of Iron at EHA2023: Novel Regulatory Mechanisms and Therapeutic Options for the Correction of Anemia
por: Vinchi, Francesca, et al.
Publicado: (2023)

The EHA2021 Annual Congress Award Winners: Celebrating Excellence in Hematology
por: Gribben, John, et al.
Publicado: (2021)

Human endoglin-CD3 bispecific T cell engager antibody induces anti-tumor effect in vivo
por: Zhong, Liping, et al.
Publicado: (2021)

Bispecific T-Cell Engagers and Chimeric Antigen Receptor T-Cell Therapies in Glioblastoma: An Update
por: Alsajjan, Roa, et al.
Publicado: (2023)

CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells
por: Jitschin, Regina, et al.
Publicado: (2018)

Co-engaging CD47 and CD19 with a bispecific antibody abrogates B-cell receptor/CD19 association leading to impaired B-cell proliferation
por: Hatterer, Eric, et al.
Publicado: (2019)

Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies
por: Viardot, Andreas, et al.
Publicado: (2020)

Bi38-3 is a novel CD38/CD3 bispecific T-cell engager with low toxicity for the treatment of multiple myeloma
por: Fayon, Maxime, et al.
Publicado: (2021)

Successful treatment of relapsed acute B-cell lymphoblastic leukemia with CD20/CD22 bispecific chimeric antigen receptor T-cell therapy
por: Liang, Zuyu, et al.
Publicado: (2020)

Autophagy, autophagy-associated adaptive immune responses and its role in hematologic malignancies
por: You, Liangshun, et al.
Publicado: (2016)

Coronavirus 2019-nCoV: A brief perspective from the front line
por: Han, Qingmei, et al.
Publicado: (2020)

CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL
por: Reusing, Sarah B., et al.
Publicado: (2021)

Immunodepletion of MDSC by AMV564, a novel bivalent, bispecific CD33/CD3 T cell engager, ex vivo in MDS and melanoma
por: Cheng, Pingyan, et al.
Publicado: (2022)

Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial
por: Thieblemont, Catherine, et al.
Publicado: (2023)

Bispecific killer cell engager with high affinity and specificity toward CD16a on NK cells for cancer immunotherapy
por: Nikkhoi, Shahryar Khoshtinat, et al.
Publicado: (2023)

Cryopreserved anti-CD22 and bispecific anti-CD19/22 CAR T cells are as effective as freshly infused cells
por: Dreyzin, Alexandra, et al.
Publicado: (2022)

Costimulatory T cell engagement via a novel bispecific anti-CD137 /anti-HER2 protein
por: Hinner, Marlon J, et al.
Publicado: (2015)

CAR T cell therapy for T cell leukemia and lymphoma: latest updates from 2022 ASH Annual Meeting
por: Huang, Qiusha, et al.
Publicado: (2023)

Cytotoxicity of the CD3×CD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targeting
por: Mhibik, Maissa, et al.
Publicado: (2023)

Correction to: CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL
por: Reusing, Sarah B., et al.
Publicado: (2021)

Highly Efficient Elimination of Colorectal Tumor-Initiating Cells by an EpCAM/CD3-Bispecific Antibody Engaging Human T Cells
por: Herrmann, Ines, et al.
Publicado: (2010)

Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab
por: Köhnke, Thomas, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ustiamkuqi9vp08ptg9aitgc9i